LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
LIXTE Biotechnology Holdings (Nasdaq: LIXT) on Oct 16, 2025 outlined Q4 priorities centered on advancing its lead candidate LB-100 and pursuing oncology-focused business development. The company said it is continuing clinical and preclinical work on LB-100 across prioritized tumor settings and maintaining collaborations with research centers.
LIXTE confirmed it is in advanced negotiations for potential acquisitions of complementary oncology assets to build a multi-asset platform, while noting no assurance any transaction will close. Operational readiness initiatives in quality, CMC, and regulatory alignment were highlighted to support study conduct and potential integration.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) il 16 ottobre 2025 ha delineato le priorità per il Q4 incentrate sull'avanzamento del suo principale candidato LB-100 e sull'inseguire lo sviluppo commerciale orientato all'oncologia. L'azienda ha detto che sta proseguendo lavori clinici e preclinici su LB-100 in contesti tumorali prioritari e mantenendo collaborazioni con centri di ricerca.
LIXTE ha confermato di trovarsi in trattative avanzate per potenziali acquisizioni di asset oncologici complementoari per costruire una piattaforma multi-asset, notando però nessuna garanzia che una transazione si chiuderà. Sono stati evidenziati iniziative di prontezza operativa in qualità, CMC e allineamento regolatorio per supportare la conduzione degli studi e una possibile integrazione.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) el 16 de octubre de 2025 delineó las prioridades del cuarto trimestre centradas en avanzar su candidato principal LB-100 y en perseguir el desarrollo empresarial enfocado en oncología. La compañía indicó que continúa con trabajos clínicos y preclínicos sobre LB-100 en entornos tumorales priorizados y mantiene colaboraciones con centros de investigación.
LIXTE confirmó que se encuentra en negociaciones avanzadas para posibles adquisiciones de activos oncológicos complementarios para construir una plataforma multi-activo, señalando al mismo tiempo sin garantía de que alguna transacción se cierre. Se destacaron iniciativas de preparación operativa en calidad, CMC y alineación regulatoria para respaldar la conducción de estudios y la posible integración.
LIXTE Biotechnology Holdings (Nasdaq: LIXT)는 2025년 10월 16일 4분기 우선순위를 주도 후보군 LB-100의 진전과 종양학 중심의 비즈니스 개발 추구에 초점을 맞춰 밝혔다. 회사는 우선순위가 지정된 종양 설정에서 LB-100에 대한 임상 및 전임상 연구를 계속하고 연구 센터와의 협력을 유지하고 있다고 말했다.
LIXTE는 보완적 종양 자산의 다자산 플랫폼 구축을 위한 잠재적 인수에 대한 고급 협상에 있음을 확인했으며, 어떤 거래도 성사될 것이라는 보장 없음을 언급했다. 연구의 수행 및 잠재적 통합을 지원하기 위한 품질, CMC 및 규제 정렬의 운영 준비 이니셔티브가 강조되었다.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) a dévoilé le 16 octobre 2025 les priorités du T4 axées sur l’avancement de son candidat principal LB-100 et la poursuite d’un développement commercial axé sur l’oncologie. L’entreprise a indiqué qu’elle poursuit des travaux cliniques et précliniques sur LB-100 dans des contextes tumoraux prioritaires et qu’elle maintient des collaborations avec des centres de recherche.
LIXTE a confirmé être en négociations avancées pour d’éventuelles acquisitions d’actifs oncologiques complémentaires afin de construire une plateforme multi-asset, tout en notant aucune garantie que transaction aboutira. Des initiatives de préparation opérationnelle en qualité, CMC et alignement réglementaire ont été mises en avant pour soutenir la conduite des études et une éventuelle intégration.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) hat am 16. Oktober 2025 die Prioritäten fürs vierte Quartal vorgestellt, die sich auf die Weiterentwicklung seines führenden Kandidaten LB-100 und die Verfolgung einer onkologieorientierten Geschäftsentwicklung konzentrieren. Das Unternehmen gab an, klinische und präklinische Arbeiten an LB-100 in priorisierten Tumorumgebungen fortzusetzen und die Zusammenarbeit mit Forschungseinrichtungen aufrechtzuerhalten.
LIXTE bestätigte, dass es sich in fortgeschrittenen Verhandlungen über potenzielle Akquisitions von ergänzenden Onkologie-Assets befindet, um eine Multi-Asset-Plattform aufzubauen, wobei darauf hingewiesen wurde, dass keine Sicherheit besteht, dass eine Transaktion abgeschlossen wird. Operative Bereitschaftsinitiativen in Qualität, CMC und regulatorischer Abstimmung wurden hervorgehoben, um die Durchführung von Studien und eine potenzielle Integration zu unterstützen.
LIXTE Biotechnology Holdings (التداول في ناسداك: LIXT) في 16 أكتوبر 2025 حددت أولويات الربع الرابع التي تركز على تقدم مرشحها الرائد LB-100 والسعي لتطوير الأعمال المعنيّة بالأورام السرطانية. وقالت الشركة إنها تتابع الأعمال السريرية وما قبل السريرية على LB-100 في بيئات ورمية ذات أولوية وتحافظ على التعاون مع مراكز الأبحاث.
أكدت LIXTE أنها في مفاوضات متقدمة للحصول على أصول أورام مناعية مكملة لبناء منصة متعددة الأصول، مع ملاحظة أن لا يوجد ضمان بأن يتم إغلاق أي صفقة. كما أُبرزت مبادرات الاستعداد التشغيلي في الجودة وCMC والمواءمة التنظيمية لدعم إجراء الدراسات والاندماج المحتمل.
LIXTE Biotechnology Holdings (纳斯达克: LIXT) 于2025年10月16日概述第四季度重点，聚焦推进其领先候选药物 LB-100 的进展，并推进以肿瘤学为重点的业务发展。公司表示将继续在优先肿瘤领域对 LB-100 进行临床和前临床研究，并与研究中心保持合作。
LIXTE 确认正在就可能收购互补的肿瘤资产进行高级谈判以建立多资产平台，同时指出任何交易都不保证一定会完成。文中还强调了在质量、CMC 和监管对齐方面的运营就绪举措，以支持研究的开展和潜在的整合。
- Continued clinical advancement of LB-100 across prioritized tumor settings
- Company in advanced negotiations for complementary oncology assets
- Operational initiatives in quality, CMC, and regulatory readiness
- Company stated no assurance that any potential transaction will complete
- No financial or transaction terms disclosed to assess shareholder impact
Company underscores clinical execution and confirms advanced negotiations
underway on acquisition of complementary oncology assets
BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today outlined its fourth-quarter 2025 priorities and provided an update on its strategic business development and acquisition initiatives focused on oncology.
“LIXTE is entering Q4 with clear operational goals and a disciplined approach to strategic expansion,” said Geordan Pursglove, Chairman and Chief Executive Officer. “We remain focused on advancing LB-100 in high-need cancer indications, while pursuing acquisitions of complementary oncology assets that could enhance our pipeline, accelerate development and create durable value for patients and shareholders.”
The Company confirmed it is in advanced negotiations regarding potential transactions consistent with its strategy, although said there can be no assurance that any transaction will be completed.
2025 Progress and Q4 Priorities
- Clinical execution: Continued advancement of LB-100 across prioritized tumor settings, supported by growing clinical and preclinical evidence and collaborations with leading research centers.
- Oncology-focused expansion: Active negotiation with synergistic or adjacent treatments, with the aim of building a differentiated, multi-asset oncology platform.
- Operational readiness: Ongoing initiatives in quality, CMC, and regulatory alignment to support efficient study conduct and potential integration of acquired programs.
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at www.lixte.com.
Forward-Looking Statement Disclaimer
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.
The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.
Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For more information about LIXTE, contact:
info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
FAQ
What did LIXT announce on Oct 16, 2025 about LB-100?
Is LIXT pursuing acquisitions and what stage are talks at (LIXT)?
How will potential acquisitions affect LIXT's pipeline and timeline (LIXT)?
What operational steps is LIXT taking to support clinical programs (LIXT)?
Did LIXT disclose financial terms or expected closing date for any acquisition (LIXT)?
Does LIXT guarantee any planned transaction will close after the Oct 16, 2025 update?
